Diclofenac Sodium Entric-coated Tablet
Diclofenac sodium enteric coated tablets (diclofenac sodium enteric coated tablets) are non steroidal anti-inflammatory drugs (NSAIDs). They can inhibit the biosynthesis of prostaglandins (PG) in the body, and have antipyretic and analgesic effects. When using NSAIDs, we should realize that age itself is an important factor in the occurrence of adverse reactions. Elderly patients are more likely to develop indigestion, gastroduodenal ulcer and bleeding, renal dysfunction, hypertension and * retention of water and sodium. NSAIDs inhibit platelet function and interact with certain drugs, including anticoagulants, oral hypoglycemic agents, anticonvulsants, antihypertensive drugs, diuretics, and corticosteroids.
Diclofenac is a non steroidal anti-inflammatory and analgesic drug derived from phenylacetic acid. Its mechanism of action is to inhibit the activity of cyclooxygenase, thus blocking the transformation of arachidonic acid into prostaglandins. At the same time, it can also promote the combination of arachidonic acid and triglyceride (triacylglycerol), reduce the concentration of free arachidonic acid in cells, and indirectly inhibit the synthesis of leukotrienes. Diclofenac is one of the most effective non steroidal anti-inflammatory drugs. Its inhibitory effect on prostaglandin synthesis is stronger than that of aspirin and indomethacin. Non clinical toxicological study: diclofenac sodium was given to rats at a dose of 2mg / kg per day. No increase in tumor incidence was found during long-term observation. In a two-year study of mice, 2 mg / kg per day did not show any tendency to develop tumors. No gene mutation induced by diclofenac sodium was found in various mutation studies. The rats were treated with 4mg / kg daily, and no infertility occurred in both sexes. Results of acute toxicity test: LD50 of rats was 150 mg / kg and that of mice was 390 mg / kg.
Audited Supplier 
){kind=link}